Researchers at the University of Cincinnati (UC) have received $2.4 million infederal funding to pursue research on a novel cell therapy that would repairheart damage using modified cells taken from the patient's own facial muscle.
Looking at a Treatment to Reduce Colon Cancer Recurrence
What: The purpose of this study is to evaluate the effects of an oral drug
called celecoxib when combined with FOLFOX chemotherapy in
patients with colon cancer who have previously been treated with
surgery. FOLFOX chemotherapy is a standard treatment used to
prevent colon cancer from coming back and consists of three drugs:
5-fluorouracil, leucovorin and oxaliplatin. This study will also look
at whether receiving FOLFOX for 6 treatments is as good as 12
treatments in preventing colon cancer from returning. Currently, the standard of care for colon cancer is 12 treatments with FOLFOX. This trial will explore whether 6 treatments are as effective as 12 treatments and whether side effects can be reduced with fewer treatments.
Who: Adults 18 years or older who have cancer of the colon, which has been surgically removed, but has spread to the lymph nodes may be eligible to participate.
Details:For more information, contact the UC Cancer Institute at firstname.lastname@example.org or 513-584-7698.